The anti-nerve growth factor (NGF) antibody fasinumab improved pain and function in patients with osteoarthritis (OA) in a phase III study in the USA. 342 patients with knee or hip OA were randomly allocated on a 1:1:1:1:1 basis to receive either placebo, or fasinumab at 1 mg, 3 mg, 6 mg or 9 mg doses, every 4 weeks for 16 weeks. All doses of fasinumab produced statistically significant and clinically important reductions in pain compared with placebo at 16 weeks. One patient receiving 6 mg fasinumab developed destructive arthropathy.
References
Original article
Dakin, P. et al. The efficacy, tolerability and joint safety of fasinumab in osteoarthritis pain: a phase IIb/III double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheumatol. https://doi.org/10.1002/art.41012 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Collison, J. Anti-NGF therapy improves osteoarthritis pain. Nat Rev Rheumatol 15, 450 (2019). https://doi.org/10.1038/s41584-019-0266-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0266-y
